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To the editor: While making their case for the immunotherapy of prion diseases, Purro et al (1) 
suggest that the toxicity of antibodies against the globular domain of the prion protein, which was 
observed in numerous studies, may be unspecific. The published literature, however, tells a 
different story (2-9). Firstly, toxicity was never observed in mice devoid of the prion protein – a 
finding impossible to reconcile with the alleged lack of antibody specificity. Secondly, toxicity was 
reproducibly blocked by preincubation of antibodies with recombinant prion protein, indicating the 
requirement for a reactive paratope. Thirdly, toxicity was reproduced with single-chain nanobodies 
directed against PrP, thereby excluding any role for complement fixation or other effector 
functions of antibodies. Fourthly, no toxic effects were observed with unrelated antibodies 
(including pooled IgG, anti-NOGO receptor and BRIC222) administered in similar paradigms. 
Fifthly, antiprion antibody toxicity was commensurate to the level of PrP expression, with 
overexpression leading to exaggerated toxicity. Sixthly, toxicity required PrP expression by 
neurons. Finally, toxicity was only seen in mice whose PrP protein contained an intact amino 
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terminus. Assuming that Purro et al (1). adhere to the conventional meaning of “specificity” in an 
immunological context (i.e. selectivity of the paratope-epitope interaction), one can safely 
conclude that said specificity is confirmed by a vast body of experimental evidence.  
Furthermore, Purro et al (1) incorrectly state that antibody toxicity was achieved only at 
micromolar concentrations. Toxicity in cerebellar organotypic cultured slices (COCS), as 
assessed by the disappearance of the NeuN neuronal marker (indicative of neuronal death within 
the internal granule cell layer), is induced by antibody POM1 at a concentration of 270 
nanomoles/liter in COCS expressing wild-type levels of PrP (4). Besides, a single exposure to 33 
nanomolar ICSM18 or POM1 is sufficient to induce spontaneous currents (a surrogate of 
neurotoxicity) in N2a cells expressing normal levels of wild-type PrPC (7). Another PrP ligand 
discussed by the authors, Aβ, suppresses long-term potentiation in hippocampal slices at 0.5-1 
μM concentrations (10-12) which are similar to (or higher than) those of toxic anti-PrP antibodies. 
Therefore, there is no factual basis to the dismissal of antibody toxicity as unspecific effects due 
to excessive concentrations.  
Purro et al (1) claim that no toxicity was seen after intrahippocampal injection of up to 2 μg of 
various anti-PrP antibodies. Again, this is not in line with the published evidence. Solforosi et al. 
described neurodegeneration upon stereotactic injection of 2 μg of antibodies P and D13 (3), and 
we reproduced neurodegeneration with D13 both in COCS and upon stereotactic injection (4, 6). 
We are aware that Klöhn and Collinge failed to confirm these findings (13), yet negative data can 
be caused by many confounders and should only be considered informative if the underlying 
mechanism is elucidated.  
Purro et al (1) incorrectly characterize the neurotoxicity described in our stereotaxic injection 
studies as “apoptosis at the cannula site” - a description presumably meant to imply mechanic 
needle damage. In reality, we reported that injection of 6 µg of antibody ICSM18 induced lesions 
of up to 1.4 mm3 (avg±SD: 0.26 ± 0.15 mm3) in wild-type female mice, which is fourteen times the 
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largest lesion (0.1 mm3) seen after control injection of 6 µg BRIC222 (avg±SD: 0.06 ± 0.05 mm3) 
(6). What is more, chronic administration of antibodies through osmotic minipumps to tga20 mice 
overexpressing PrP (14) resulted in massive destruction of up to 13% (avg±SD; 9±3%) of the total 
brain volume (Fig. 1 and ref. (6)).   
Purro et al (1) refer to an effective dose with no adverse effects of 1 μg/h for antibody 31C6 (total 
dose 336 μg, 14 days (15)) and claim a therapeutic range of 2 logs. This alleged lack of toxicity 
may not be fully informative since 31C6 does not interact with helix-3 of PrP (16). While we did 
not have the opportunity to study antibody 31C6, we found that chronic administration of an 
equimolar amount of POM1 induces massive tissue damage in tga20 mice (Fig. 1) as early as 
four days (cumulative dose: 14.4 μg POM1 scFv) after minipump implantation (diffusion-weighted 
magnetic resonance imaging, Figure 4 in (6)). One can only hope that such dramatic adverse 
effects will remain confined to PrP-overexpressing mice.  
Purro et al (1) note that Klyubin et al. failed to detect neurotoxicity upon intracerebroventricular 
administration of 30 μg and intracardiac administration of 6mg of antibody PRN100 (17). While 
this is encouraging, their analysis was limited to histology 4 hours after intracerebroventricular 
injection and 14 hours after intracardiac administration. At this early time point, only minimal 
lesions are detectable by magnetic resonance imaging, arguably the most sensitive indicator of 
damage (Figure 4 in ref. (4)), and histology revealed early signs of neurodegeneration only in 
tga20 mice challenged intracerebrally with 6 µg antibody (Supplementary Figure 13 in ref. (4)). 
Purro et al (1) mention a single ascending dose-finding study of PRN100 in cynomolgus monkey 
at intravenous doses up to 200 mg/kg allegedly described by Klyubin et al (17). However, the 
actual data are not shown in the cited publication and do not seem to be publicly available.  
In summary, we commend and share the enthusiasm with which Purro et al. promote antibody 
therapies against prions. Like them, we feel for the patients affected by these terrible diseases. 
However, the interests of patients are best served by reading and correctly interpreting the 
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available literature, and by addressing any safety flags dispassionately, collaboratively, and 
without preconceptions. 
 
Figure Legends 
Figure 1: Gross brain destruction induced by chronic exposure to antibody POM1. 
Representative micrographs of tga20 mouse brains (immunostaining: glial fibrillary acidic protein) 
21 days after the implantation of a mini-osmotic Alzet pump delivering a single-chain variable 
fragment (scFv) of POM1 (0.15 µg/h, cumulative dose of 75 µg) intracerebroventricularly. Gross 
damage to the brain architecture with conspicuous hydrocephalus e vacuo indicative of tissue 
loss. Note the massive astrogliosis extending to the contralateral hemisphere. In contrast, no 
lesion was detected in Prnp°/° mice. Adapted from Reimann et al (6). 
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